Natural History of Type 1 Interferonopathies: Insights From a European Cohort
Recruiting now
Conditions studied: Genetic Disease, Immune Dysfunction, Neurological Diseases or Conditions, Autoimmune Diseases
In brief
Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed. Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear. In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies. The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies. The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.
Key facts
- Study ID
- NCT07040774
- Run by
- Imagine Institute
- People needed
- 500
- Starts
- 2025-10-01
- Expected to finish
- 2045-10-01
- Last updated by the study team
- 2026-05-13
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Genetically confirmed patient with type I interferonopathy
- Patient affiliated to a social security scheme or beneficiary of such a scheme.
You may not qualify if…
- Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.
Where it is running
- CHU de Nantes — Nantes, France (enrolling)
- CH Agen-Nérac — Nérac, France (enrolling)
- Hôpital de l'Archet — Nice, France (enrolling)
- CHU Morvan — Brest, France (enrolling)
- Hôpital Femme Mère Enfant - HCL — Bron, France (enrolling)
- Hôpital de Mercy - CHR Metz Thionville — Ars-Laquenexy, France (enrolling)
- Hôpital des Enfants - CHU de Toulouse — Toulouse, France (enrolling)
- Hôpital Necker Enfants Malades — Paris, Île-de-France Region, France (enrolling)
- Hôpitaux Nord Ouest Villefranche — Gleizé, France (enrolling)
- CHU de Besançon — Besançon, France (enrolling)
- CHU d'Angers — Angers, France (enrolling)
- APHM Hôpitaux de Marseille — Marseille, France (enrolling)
- CHU de Montpellier — Montpellier, France (enrolling)
- Hacettepe İhsan Doğramacı Children's Hospital — Ankara, Turkey (Türkiye) (enrolling)
- CHRU Nancy — Nancy, France (enrolling)
- Karolinska University Hospital — Stockholm, Sweden
- Medical University Innsbruck — Innsbruck, Austria
- Leeds Teaching Hospitals NHS Trust — Leeds, United Kingdom
- Antwerp University Hospital — Antwerp, Belgium
- Children's Hospital Zagreb — Zagreb, Croatia
- Motol University Hospital — Prague, Czechia
- CHU de Bordeaux — Bordeaux, France
- CHU de Dijon — Dijon, France
- Hôpital Bicêtre — Le Kremlin-Bicêtre, France
- Hôpital Claude Huriez, CHU de Lille — Lille, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.